Why Ireland Is Europe's Premier Pharmaceutical Manufacturing Destination
Ireland's ascent to the top tier of global pharmaceutical manufacturing is no accident. Over the past four decades, the country has built a world-class life sciences ecosystem — anchored by a pro-business tax environment, a highly educated English-speaking workforce, and deep government support through IDA Ireland. Today, nine of the world's ten largest pharmaceutical companies operate significant facilities on the island, and Ireland ranks as the world's third-largest exporter of pharmaceuticals by value, with annual exports exceeding €100 billion.
For contract manufacturers and CDMOs, Ireland offers a uniquely compelling combination: proximity to both European and US markets, full alignment with FDA and EMA regulatory frameworks, a robust cluster of pharma-trained scientists and engineers, and a thriving network of specialist suppliers, CROs, and analytical laboratories. From the high-potency API corridors of Cork and Waterford to the cell-therapy suites of Galway, Ireland's CDMO sector covers the full spectrum of modern drug manufacturing.
Why Pharma Companies Choose Ireland for CDMO Services
Ireland offers a rare combination of scientific talent, regulatory excellence, and strategic geography that no other single European country can match.
Regulatory Dual Compliance
Ireland-based facilities routinely hold both FDA and EMA approval, making them uniquely positioned to supply global markets from a single site.
Skilled Workforce
Over 80,000 people work in the Irish life sciences sector. Seven of Ireland's eight universities offer science, engineering, and pharmacy programs aligned with industry needs.
Favourable Tax Environment
Ireland's 12.5% corporation tax rate and Knowledge Development Box (KDB) providing a 6.25% rate on IP income make it one of the most competitive business environments in Europe.
EU Market Gateway
As the only English-speaking nation remaining in the EU, Ireland provides seamless access to a 450 million-person market, simplifying regulatory submissions, labelling, and supply chain logistics.
IDA Ireland Support
IDA Ireland provides R&D&I grants that routinely cover 45–50% of the cost of large-scale, multi-year innovation projects, dramatically reducing the cost of establishing or expanding CDMO capacity.
Track Record of Excellence
Ireland has zero major pharma product recalls attributable to manufacturing failure in the past decade — a track record that speaks to the culture of GMP compliance embedded across the Irish pharma cluster.
Hovione is a globally recognized independent CDMO and a world leader in spray drying for pharmaceutical applications — a technology that is especially critical for inhalable therapies and oral drugs with low bioavailability. Founded in Lisbon in 1959 and now operating across four continents, Hovione's Cork facility is one of the company's most strategically important sites, housed at the former Pfizer Lipitor API plant in Ringaskiddy, which Hovione acquired in 2008.
The Cork site specializes in integrated API synthesis, particle design, and pharmaceutical formulation development and manufacturing. The facility operates 24 hours a day, seven days a week, with quality control laboratories running continuous support. In recent years, Hovione has made multi-million-euro investments to nearly double its spray drying capacity in Cork, reinforcing the site's position as the company's European centre of excellence for spray drying. A new Process R&D group expansion was also completed in 2024, alongside a highly potent small-scale equipment suite to support clinical trial and registration campaigns.
The Ringaskiddy site handles active pharmaceutical ingredients up to OEB 4 and supports the use of organic solvents, making it suitable for complex and sensitive APIs. Hovione's spray drying platform in Cork is supplied by leading equipment manufacturers including Büchi and GEA, giving the site the technical range to produce both amorphous solid dispersions for oral drugs and inhalation powders for respiratory therapies.
Thermo Fisher Scientific's Cork site — operating under the Patheon CDMO brand — is one of Ireland's largest and most technically sophisticated API contract development and manufacturing facilities. The site was acquired from GlaxoSmithKline (GSK) in 2019 for approximately €90 million and has since undergone a remarkable transformation: since take-over, the plant has increased its manufacturing capacity fivefold, now servicing over 20 global pharmaceutical customers.
Located in Ringaskiddy, County Cork, the facility employs over 500 highly skilled chemists, engineers, analysts, and manufacturing operators, with a sister analytical and laboratory services site in Athlone employing a further 400. The Cork site has a proud manufacturing heritage stretching back 45 years, originally producing active pharmaceutical ingredients for GSK's global portfolio, and now supporting a broad range of innovative medicines.
The site's specializations include contract API development and manufacturing for complex small molecules, with a particular focus on treatments for childhood cancer, Parkinson's disease, and depression. Thermo Fisher's Cork facility supports customers through the full development lifecycle — from process and analytical development through scale-up to commercial API supply. The Athlone laboratory complement extends this offering into stability testing and method development services.
EirGen Pharma is one of Ireland's most impressive home-grown pharmaceutical success stories. Founded in Waterford in 2005, the company has built a two-decade track record as a global leader in the development and manufacture of high-potency oral solid dose (OSD) medicines, with a particular specialization in oncology treatments, rare diseases, and cytotoxic applications for both human and veterinary use.
EirGen's Waterford campus currently spans 40,000 square feet of dedicated GMP manufacturing space. The company is in the midst of a major expansion — a 3,500 m² high-containment manufacturing building is currently under construction and is scheduled to be fully operational by late 2025. Once complete, this new facility is specifically designed to accommodate accelerated technology transfers, complex formulation requirements, and the next generation of high-potency cancer therapies.
EirGen currently produces 520 million dosage units annually, serving more than 120 pharmaceutical partners across 60 countries. By 2027, the expanded Waterford facility is projected to reach a capacity of 1 billion dosage units per year — a near-doubling of output that underscores the company's ambition and the strength of global demand for its specialized manufacturing expertise. EirGen's product portfolio spans softgel capsules, film-coated tablets, and powder or liquid-filled hard-shell capsules, all produced under the stringent containment requirements of high-potency API handling.
The Aenova Group's Killorglin facility — operated as Temmler Ireland Ltd. — is one of Europe's most experienced oral solid dose contract manufacturing sites, with almost 50 years of continuous operation in County Kerry. Aenova is a leading pan-European CDMO with sites across Germany, Switzerland, Italy, Romania, and Ireland, and the Killorglin site functions as the group's designated Competence Center for spray drying and modified release pellets.
In early 2025, Aenova launched a significant new spray drying platform at Killorglin — equipped by Büchi and GEA — specifically designed to produce amorphous solid dispersions (ASD) for oral medicines with challenging bioavailability profiles, as well as inhalation powders. This investment positions the Killorglin site at the forefront of a technology that is increasingly critical for new drug formulations, where poorly soluble drug candidates represent a growing share of the pipeline.
The Killorglin facility supports active pharmaceutical ingredients up to OEB 4 potency class and is capable of handling organic solvents, giving it the flexibility to work with complex compounds. Its modified release pellet production line encompasses granulation, coating, encapsulation, and extraction, with capabilities ranging from small development batches through full commercial scale. The site supports customers from preclinical through to Phase IV commercial manufacturing.
HiTech Health holds a distinctive place in Ireland's life science ecosystem: it was the first Irish company to secure a manufacturing licence to produce cell and gene therapies on behalf of client biotech and biopharma companies. Founded in 2013, HiTech Health is an end-to-end ATMP (Advanced Therapy Medicinal Product) CDMO operating from a purpose-built GMP facility in Galway, certified by Ireland's Health Products Regulatory Authority (HPRA) and compliant with all European GMP standards.
The Galway facility was specifically designed and built to advance the development, manufacturing, and testing of sterile formulations such as cell and gene therapies, lentiviral vectors, and other advanced biologics. HiTech Health provides end-to-end ATMP services spanning cell and gene therapy drug substance manufacturing (API), drug product formulation (FDF), research and development, and the production of clinical trials materials. The facility also provides batch importation and formal release for the EU and UK markets.
What distinguishes HiTech Health in a competitive market is its specialised logistics capability for time- and temperature-sensitive therapies — a critical competency in advanced therapeutics where cold chain integrity is directly linked to product efficacy and patient safety. Their regulatory consulting team supports sponsors through EMA, FDA, and HPRA approval processes, substantially de-risking the journey from first-in-human studies to late-stage clinical supply.
PCI Pharma Services is a leading global CDMO providing integrated drug development, manufacturing, and packaging services for pharmaceutical and biotechnology companies. PCI's Irish operations are anchored at CityNorth Business Campus in Stamullen, County Meath — a strategically chosen location that benefits from excellent road and air connectivity to both Dublin and the north of Ireland.
PCI's existing 45,000 square foot facility at the Meath campus has been joined by a major new development: the company has signed a 25-year lease and is constructing a purpose-built 82,000 square foot pharmaceutical packaging facility at the same campus. The new facility, targeting completion in 2025, is designed specifically for the final assembly, labelling, and packaging of injectable drug products — including vials, pre-filled syringes (PFS), and drug-device combination products such as autoinjectors and combination pens, which represent the fastest-growing segment in biologics packaging.
The new Meath facility is being built to high sustainability standards, targeting LEED Gold certification alongside an A3 Building Energy Rating and rainwater harvesting systems — reflecting both client and regulatory expectations for environmental responsibility in new pharmaceutical facilities.
Almac Group is one of the most comprehensive CDMOs operating on the island of Ireland, with its global headquarters campus at Craigavon in Northern Ireland. As a fully independent, family-owned company, Almac has invested aggressively in capacity across its service lines — from drug discovery and pre-clinical development, through clinical trial supply, active pharmaceutical ingredient (API) manufacturing, to full commercial production and specialty packaging.
Almac's recent capital investment program has been substantial. In March 2025, the company officially opened a new £65 million commercial manufacturing facility at Craigavon — one of the largest single pharmaceutical manufacturing investments in Northern Ireland's history. This facility substantially increases Almac's output capacity for complex commercial drug products, including advanced sachet presentations.
A particular area of growth for Almac is peptide API manufacturing, which is now one of the fastest-growing niches in pharmaceutical outsourcing, driven by the explosion of GLP-1 and other peptide-based therapies globally. A dedicated 28,000 square foot GMP peptide synthesis and purification facility was completed in early 2025, more than doubling Almac Sciences' peptide manufacturing capacity. The facility supports synthesis, purification, and isolation of peptide APIs for both clinical development campaigns and commercial supply.
Wasdell Group is a UK-based contract service partner with a significant Irish presence, having invested €30 million in constructing a purpose-built 90,000 sq ft GMP pharmaceutical packaging and distribution facility in Mullagharlin, Dundalk. Wasdell's Dundalk site was established specifically to serve its pharmaceutical clients requiring EU-based supply chains post-Brexit — and it has grown into a strategic hub for both clinical and commercial packaging operations in Ireland.
The Dundalk facility houses 11 production suites equipped with state-of-the-art packaging technologies, including blister packing lines, bottle filling and capping, and clinical kit assembly. The site also includes fully equipped quality control import testing laboratories, temperature-controlled high-bay warehousing, and full serialisation capability for track-and-trace compliance across EU and international markets.
Wasdell Dundalk holds a Manufacturer's/Importation Authorisation (MIA) licence granted by Ireland's HPRA, a separate Investigational Medicinal Product (IMP) licence for clinical trial materials, and ISO 13485 certification for medical device packaging — making it one of Ireland's most comprehensively licensed contract packaging organisations. The facility services both oral solid dose and sterile injectable products, with temperature-controlled storage ranging from ambient to cryogenic conditions.
Q1 Scientific, now part of the global CDMO Cambrex, is a specialist cGMP stability storage and testing company founded in Waterford in 2013. Acquired by Cambrex in 2022, the Waterford facility has grown to become a critical node in the European pharmaceutical stability testing network — providing environmentally controlled stability storage services to pharmaceutical, medical device, and life science companies across the EU and globally.
The Waterford cGMP facility offers the full ICH climatic zone storage conditions required for drug development and registration — from Zone I (temperate) through Zone IV (hot and humid) — alongside custom temperature and humidity conditions for non-standard stability programs. The site houses nearly 40 walk-in stability storage chambers, reach-in freezers, stability units, and ultra-low temperature freezers (down to -80°C) for biologic therapies and advanced medicinal products requiring cryogenic conditions.
Following its acquisition, Cambrex invested in expanding the Waterford site with an additional 10,000 square feet of stability storage capacity, bringing the total site to 30,000 sq ft. Q1 Scientific's Waterford facility also provides stability program design support, sample management, and reporting services — giving sponsors a fully managed end-to-end stability solution to support regulatory submissions worldwide.
Ireland CDMO Companies — Quick Reference Table
Use this table to quickly compare the leading CDMO companies in Ireland by location, primary specialization, regulatory approvals, and key facts to shortlist the right manufacturing partner for your drug program.
| CDMO Company | Location | Primary Specialization | Regulatory Status | Key Highlight |
|---|---|---|---|---|
| Hovione | Ringaskiddy, Cork | API, Spray Drying, Inhalation | FDA, EMA | Global leader in spray drying for pharma |
| Thermo Fisher (Patheon) | Ringaskiddy, Cork | API Drug Substance, Process Chemistry | FDA, EMA | 5× capacity growth since 2019; 500+ staff |
| EirGen Pharma | Waterford | High-Potency OSD, Oncology, Softgel | FDA, EMA, HPRA | 1 billion units/year capacity by 2027 |
| Aenova (Killorglin) | Killorglin, Kerry | Oral Solids, Spray Drying, Mod. Release | EMA, MFDS, ISO | ~50 years on-site; EU Competence Centre |
| HiTech Health | Galway | Cell & Gene Therapy (ATMP), Biologics | HPRA, EMA, FDA | First Irish ATMP CDMO licence holder |
| PCI Pharma Services | Stamullen, Meath | Injectable Packaging, Drug-Device Combo | FDA, EMA, HPRA | New 82,000 sq ft facility (2025) |
| Almac Group | Craigavon, N. Ireland | Peptide API, Commercial Mfg, Clinical Supply | FDA, EMA, MHRA | £65M new commercial facility opened 2025 |
| Wasdell Group | Dundalk, Louth | Clinical & Commercial Packaging | HPRA MIA, FDA, ISO 13485 | €30M facility; 11 production suites |
| Cambrex (Q1 Scientific) | Waterford | cGMP Stability Storage & Testing | HPRA, EMA, FDA | ~40 chambers; −80°C to +50°C range |
Choosing the Right CDMO Partner in Ireland
Ireland's CDMO landscape is one of the most diverse and capable in Europe. From world-class API manufacturers and spray drying specialists in Cork, to high-potency oral dose leaders in Waterford, pioneering cell therapy manufacturers in Galway, and fully licensed clinical packaging operations in Meath and Louth — the island offers a remarkably complete range of contract manufacturing capabilities under a single regulatory umbrella.
When selecting an Ireland-based CDMO, pharmaceutical sponsors and biotech companies should consider the following key factors:
- Dosage form and molecule type: API synthesis, OSD, sterile injectables, biologics, ATMP, and packaging all require specialist facilities and regulatory licenses.
- Development stage: Some CDMOs in Ireland specialize in early-phase clinical supply; others have the scale and quality systems for full commercial manufacturing.
- Regulatory market access: Most Irish CDMOs hold dual FDA/EMA approval, but confirm the specific markets and regional authorities required for your product.
- Potency and containment: High-potency API projects require OEB-rated containment; not all Irish CDMOs offer this — EirGen, Hovione Cork, and Aenova Killorglin are key options.
- Capacity timeline: With strong global demand for CDMO services, schedule early conversations with preferred partners to align on project timelines and slot availability.
Ireland's pro-investment environment continues to attract new CDMO capacity. The pipeline of announced expansions — from EirGen's containment building to PCI's new injectable packaging hub to Almac's peptide synthesis facility — signals that the island's role in global pharmaceutical contract manufacturing will only grow through the remainder of this decade.
